AMGEN INC false 0000318154 0000318154 2023-05-19 2023-05-19 0000318154 us-gaap:CommonStockMember 2023-05-19 2023-05-19 0000318154 us-gaap:SeniorNotesMember 2023-05-19 2023-05-19

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)

May 19, 2023

Amgen Inc.

(Exact name of registrant as specified in its charter)

 

Delaware   001-37702   95-3540776
(State or other jurisdiction
of incorporation)
  (Commission
File Number)
  (IRS Employer
Identification No.)

One Amgen Center Drive

Thousand Oaks

California

  91320-1799
(Address of principal executive offices)   (Zip Code)

Registrant’s telephone number, including area code

(805) 447-1000

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common stock, $0.0001 par value   AMGN   The Nasdaq Stock Market LLC
2.000% Senior Notes due 2026   AMGN26   The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 


Item 5.07. Submission of Matters to a Vote of Security Holders.

The Company held its Annual Meeting on May 19, 2023. The final results of the voting for each matter submitted to a vote of stockholders at the meeting are as follows:

Item 1 - Election of Directors

Each of the following 13 nominees for director were elected to serve a one-year term expiring at the Company’s 2024 annual meeting of stockholders and until his or her successor is elected and qualified, or until his or her earlier retirement, resignation, disqualification, removal or death.

 

Name    Votes For    Votes Against    Abstain   

Broker Non-

Votes

Dr. Wanda M. Austin

   394,173,521    3,600,031    713,436    64,052,659

Mr. Robert A. Bradway

   370,844,134    24,470,758    3,172,096    64,052,659

Dr. Michael V. Drake

   393,354,813    4,340,821    791,354    64,052,659

Dr. Brian J. Druker

   394,385,167    3,320,183    781,638    64,052,659

Mr. Robert A. Eckert

   366,786,098    30,895,580    805,310    64,052,659

Mr. Greg C. Garland

   348,891,130    48,785,661    810,197    64,052,659

Mr. Charles M. Holley, Jr.

   375,952,849    21,719,176    814,963    64,052,659

Dr. S. Omar Ishrak

   394,074,365    3,631,310    781,313    64,052,659

Dr. Tyler Jacks

   388,385,762    9,306,550    794,676    64,052,659

Ms. Ellen J. Kullman

   382,005,978    15,755,078    725,932    64,052,659

Ms. Amy E. Miles

   379,723,549    18,027,013    736,426    64,052,659

Dr. Ronald D. Sugar

   361,610,515    36,064,512    811,961    64,052,659

Dr. R. Sanders Williams

   380,631,476    17,063,281    792,231    64,052,659

Item 2 - Advisory Vote on the Frequency of Future Stockholder Advisory Votes to Approve Executive Compensation

One year was selected for the advisory vote on the frequency of future stockholder advisory votes to approve executive compensation based upon the following votes:

 

One Year:

  390,912,836

Two Years:

  888,684

Three Years:

  5,869,436

Abstain:

  816,032

Broker Non-Votes:

  64,052,659

Consistent with our Board of Directors’ recommendation in our 2023 Proxy Statement and the vote of our stockholders, our Board of Directors has determined that the stockholder advisory vote on executive compensation will occur on an annual basis (every “one year”).

Item 3 - Advisory Vote to Approve Our Executive Compensation

The advisory vote to approve our executive compensation was approved.

 

For:

  371,994,642

Against:

  23,910,086

Abstain:

  2,582,260

Broker Non-Votes:

  64,052,659


Item 4 - Ratification of Selection of Independent Registered Public Accountants

Ernst & Young LLP was ratified as the Company’s independent registered public accountants for the fiscal year ending December 31, 2023. No Broker Non-Votes resulted from the vote on this proposal.

 

For:

  438,448,567

Against:

  23,252,562

Abstain:

  838,518

No other matters were submitted for stockholder action.


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    AMGEN INC.
Date: May 22, 2023   By:     /s/ Jonathan P. Graham
   

 

    Name:   Jonathan P. Graham
    Title:   Executive Vice President and General Counsel and Secretary